Months ago, we were deluged by emails and phone calls from thyroid patients in several countries. Many were troubled, and others were terrified. The reason is that they were no longer able to obtain Cynomel from offshore pharmacies. For those who don't know, Cynomel was a synthetic T3 product that, in my experience, was equally as effective as Cytomel, and was more stable. In my person use of each product for many years, I had far fewer experiences with subpotent tablets with Cynomel. .....dietary and organic.... Cynomel had rescued the patients who contacted us from misery imposed on them by the endocrinology specialty's cash cow, T4 replacement with levothyroxine. Many of the patients purchased Cynomel from offshore pharmacies and benefited from the secrete guidance of caring local clinicians. Why do I say "secrete" guidance"? Because the clinicians (many of whom I have talked with) were afraid of retaliation from local endocrinologists. Retaliation for what—getting a patient well with an approach to thyroid hormone therapy other than T4 replacement. Never mind that a patient—in fact many patients—got well; that is apparently of no concern to the endo who files a complaint against a clinician who was naughty enough get a patients well with a therapy other than T4 replacement. I'll get off my soap box and stop my harangue over the inhumanity of some humans toward other humans. The bottom line is that, as we assured the patients who contacted us, we would find an effective alternative to Cynomel. The product, "Hypo Support Formula" (which we call "HSF" for short), is highly effective, and we have some evidence that it provides some benefits beyond those that Cynomel provided. We encourage you to read the report at Thyroid Science of the first clinical trial in which HSF was compared to Cynomel. The report of the second trial will be published within a week or so. If you have questions about anything in the report, please send them to info@thyroidscience.us. Patients do not need a prescription for HSF; it is protected from FDA regulation by the 1994 Dietary Supplement Health and Education Act. But please beware: Effective alternatives to prescription medications are constant under threat of being removed from the market as competitors of the prescription medications. The FDA needs little excuse to take action to protect the financial interests of big pharma, and so using HSF safely is crucial to it continuing to be available to you to use, if you choose, to protect your health and your quality of life. HSF is now available at www.ThyroidScience.US. If your pharmacist carrying the product, or if your clinician is interested in using it with other patients, he or she can send an email to customerservice@thyroidscience.us. Of course, you are free to order HSF directly from www.ThyroidScience.US.
I am immensely satisfied with the success of the open-access online journal, Thyroid Science, that I started some three years ago. We have published a wide range of papers. The authors of some are veteran practicing thyroid clinicians; the authors of others are thyroid researchers at prestigious medical institutions in a variety of countries. Personally, I am fascinated by some of the highly technical and academic papers we've published. But, of course, it is the papers that have the most practical implications that are of most value to the majority of our readers. Today, we published a paper that I feel should be important to pregnant women. The senior investigator of the study is P. Pasupathi, PhD, Head of the Department of Clinical Biochemistry, Bio Line Research Institute in Coimbatore, Tamil Nadu, India. Dr. Pasupathi and his research team studied changes in women's thyroid lab test results during their three trimesters of pregnancy, and they compared the levels with those of women who were not pregnant. The authors recommend that research do similar studies of women in different geographical regions. The aim is to establish the typical levels five thyroid tests (the TSH, and the total and free T4 and T3 levels). Dr. Pasupathi and his research team believe that if clinicians know what changes in the levels of these hormones typically are during the different trimesters, then the clinicians can avoid making misdiagnoses and prescribing improper treatment of pregnant women based on the misdiagnoses. As most readers of drlowe.com are well aware, I don't think a lot of thyroid function test results, not unless they are reliably far out of range. And I don't believe clinical decisions should ever be made based solely on the TSH and thyroid hormone levels—not without consideration of the patient's history, current clinical status, and relevant physiological measures. I believe that Professor Pasupathi would agree with this point of view. Nonetheless, I believe that the aim of his study of pregnant compared to non-pregnant women is worthwhile. The more we can learn about the changes in laboratory test results that are characteristic of the different trimesters will serve a valuable purpose: arming clinicians who care for pregnant women with more information by which they may be able to help the women and new ones they carry during pregnancy. We are proud to publish Professor Pasupathi's new report, and we hope that pregnant women and their clinicians find his study results of practical use.
If you want to discuss the services we provide, please contact me. You can reach me by email at Tammy@drlowe.com or by phone at 603-391-6061. Dr. John C. Lowe, PLLC © 2009 John C. Lowe, MA, DC, DAAPM. All rights reserved. This email newsletter may be copied and distributed subject to three conditions: (1) All text within the full document or any section copied must be copied without modification with all pages included. (2) All copies must contain the following copyright notice: "© 2009 John C. Lowe." (3) Neither this full document nor any section of it may be published or distributed for profit. |
|||
